Narashino, Japan

Susumu Kitanaka


Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 1999-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Susumu Kitanaka: Innovator in Anticancer and Allergy Treatments

Introduction

Susumu Kitanaka is a notable inventor based in Narashino, Japan. He has made significant contributions to the fields of medicine and pharmaceuticals, particularly in the development of treatments for cancer and allergic diseases. With a total of two patents to his name, Kitanaka's work reflects a commitment to advancing healthcare solutions.

Latest Patents

Kitanaka's latest patents include an anticancer agent and a method for treating atopic dermatitis. The anticancer agent is designed for cancers characterized by an abundance of cyclin D1 protein, featuring a compound represented by a specific formula as its active ingredient. The second patent outlines a method of treating patients suffering from allergic diseases by administering a pharmaceutical composition that includes a dry powder of guava leaves.

Career Highlights

Throughout his career, Kitanaka has worked with various companies, including O.S. Industry Co., Ltd. His innovative approaches have led to the development of effective treatments that address critical health issues.

Collaborations

Kitanaka has collaborated with notable individuals in his field, including Sadao Hamada and Shohei Miyata. These partnerships have contributed to the advancement of his research and the successful implementation of his inventions.

Conclusion

Susumu Kitanaka's contributions to medical innovation, particularly in anticancer and allergy treatments, highlight his role as a significant inventor in the pharmaceutical industry. His work continues to impact the lives of many patients, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…